Gomez-PeraltaF, AbreuC, Gomez-RodriguezS, et al.Insulclock: a novel insulin delivery optimization and tracking system. Diabetes Technol Ther, 2019; 21: 209–214.
2.
The Other Pancreas. DIY Bluetooth insulin pump. YouTube, April 5, 2019. 1:22. www.youtube.com/watch?v = qwzOXXWGJxM.
3.
PhillipM, NimriR, BergenstalRM, et al.Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev, 2023; 44: 254–280.
4.
KastnerJR, BaileyTS, StrangeP, et al., Progressive acceleration of insulin exposure over 7 days of infusion set wear. Diabetes Technol Ther, 2023; 25: 143–147.
5.
RegittnigW, TschaiknerM, TucaAC, et al.Insulin induces a progressive increase in the resistance of subcutaneous tissue to fluid flow: implications for insulin pump therapy. Diabetes Obes Metab, 2022; 24: 455–464.
6.
PatelPJ, BenasiK, FerrariG, et al.Randomized trial of infusion set function: steel versus teflon. Diabetes Technol Ther, 2014; 16: 15–19.
7.
BrazgR, GargSK, BhargavaA, et al., Evaluation of extended infusion set performance in adults with type 1 diabetes: infusion set survival rate and glycemic outcomes from a pivotal trial. Diabetes Technol Ther, 2022; 24: 535–543.
8.
LalRA, HsuL, ZhangJ, et al.Longevity of the novel ConvaTec infusion set with Lantern technology. Diabetes Obes Metab, 2021; 23: 1973–1977.
9.
HeinemannL, KrinelkeL.Insulin infusion set: the Achilles heel of continuous subcutaneous insulin infusion. J Diabetes Sci Technol, 2012; 6: 954–964.
10.
WaldenmaierD, ZschornackE, BuhrA, et al.A prospective study of insulin infusion set use for up to 7 days: early replacement reasons and impact on glycemic control. Diabetes Technol Ther, 2020; 22: 734–741.
11.
KanapkaLG, LumJW, BeckRW.Insulin pump infusion set failures associated with prolonged hyperglycemia: frequency and relationship to age and type of infusion set during 22,741 infusion set wears. Diabetes Technol Ther, 2022; 24: 396–402.
12.
SwinneyMR, CoxAL, HawkinsED, et al.Insulin, not the preservative m-Cresol, instigates loss of infusion site patency over extended durations of CSII in diabetic swine. J Pharm Sci, 2021; 110: 1418–1426.
13.
PickupJC.Diabetes: insulin pumps after injections and CGM in T1DM. Nat Rev Endocrinol, 2017; 13: 568–569.
14.
MarillyE, CottinJ, CabreraN, et al.SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia, 2022; 65: 2000–2010.
15.
FríasJP, DaviesMJ, RosenstockJ, et al., Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med, 2021; 385: 503–515.
16.
ReznikY, CohenO, AronsonR, et al.Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial. Lancet,, 2014; 384: 1265–1272.
17.
DalyAB, BoughtonCK, NwokoloM, et al.Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. Nat Med, 2023; 29: 203–208.
18.
MartensT, BeckRW, BaileyR, et al.Effect of continuous glucose monitoring on glycemic control in patients with type 2 diabetes treated with basal insulin: a randomized clinical trial. JAMA, 2021; 325: 2262–2272.
19.
ElSayedNA, AleppoG, ArodaVR, et al.7. Diabetes technology: standards of care in diabetes—2023. Diabetes Care, 2023; 46(Suppl 1): S111–S127.
20.
National Diabetes Audit, 2019–20, Type 1 Diabetes. NHS Digital; August 12, 2021. https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit/national-diabetes-audit-2019-20-type-1-diabetes.
21.
Ministry of Housing, Communities & Local Government. English Indices of Deprivation 2019. Gov.uk; 2020. Accessed August10, 2023. www.gov.uk/government/statistics/english-indices-of-deprivation-2019.
22.
TalebN, MessierV, Ott-BraschiS, et al.Perceptions and experiences of adult patients with type 1 diabetes using continuous subcutaneous insulin infusion therapy: results of an online survey. Diabetes Res Clin Pract, 2018; 144: 42–50.
